# CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

> **NCT02697136** · PHASE3 · TERMINATED · sponsor: **Cerenis Therapeutics, SA** · enrollment: 30 (actual)

## Conditions studied

- Familial Hypoalphalipoproteinemia

## Interventions

- **DRUG:** CER-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02697136
- **Lead sponsor:** Cerenis Therapeutics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2018-10
- **Final completion:** 2018-12-21
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697136, "CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02697136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*